Introduction
A number of novel respiratory viruses have been identified since 2001, of which human metapneumovirus and the new human coronaviruses, SARS, NL63 and HKU1, have been shown to contribute significantly to the burden of acute respiratory infections (ARIs).
In 2005, a new member of the Parvoviridae family, named human bocavirus (HBoV) because of its similarity to bovine and canine parvovirus, was discovered during random polymerase chain reaction (PCR) ⁄ cloning techniques in respiratory samples. Human bocavirus has been found in respiratory specimens by many groups of investigators worldwide, with prevalence ranging from 1AE5% to 18%. [1] [2] [3] However, it is not yet clear to what extent HBoV causes clinically relevant diseases as most studies were retrospective, examining archival respiratory samples previously tested for respiratory viruses using different techniques, and HBoV is frequently found as a co-infection.
As a part of a larger study to characterize respiratory virus infections, hospitalized children were tested for HBoV and 13 other viruses to define the prevalence of HBoV in Rome; an analysis was then undertaken of the distribution and demography of those who were HBoV positive.
Methods

Specimen collection and nucleic acid extraction
Children (below 14 years of age) admitted to the Umberto I Hospital Pediatric Department (Sapienza University, Rome) with diagnoses of asthma, bronchiolitis, bronchopneumonia, laryngo-tracheo bronchitis were enrolled in the study after parental consent had been obtained. The study was approved by the institution's Ethics Committee. The exclusion criterion was any underlying medical problem (e.g. premature birth, congenital disease, cystic fibrosis). A total of 415 children were tested between November 2004 and May 2007; all patients were admitted to hospital (median length of stay: 3 days) and were not subjected to intensive care. Nasal washings were obtained at the time of hospital admission -3 ml of sterile physiological saline solution were injected into each nostril and collected with a syringe. 4, 5 All samples were delivered on ice within 1-2 hours to the virology laboratory and on arrival, if needed, they were vortexed with beads to solve mucus; 200 ll of each specimen were then subjected to nucleic acid extraction using a Total Nucleic Acid Isolation Kit (Roche Diagnostics, Mannheim, Germany).
PCR-based assays for respiratory viruses
Reverse transcription-PCR and PCR assays were performed on the nucleic acid extracted from the nasal washes to detect HBoV and 13 other respiratory viruses; nasal washings collected between November 2004 and October 2006 were tested for HBoV retrospectively.
The specific assays for influenza A and B, respiratory syncytial virus (RSV), coronaviruses OC43 and 229E, adenovirus, rhinovirus, parainfluenza viruses (PIV) 1-3, metapneumovirus, and coronaviruses NL63 and HKU1 have been described previously. 4 For HBoV detection, two published PCR assays 1, 6 amplifying, respectively, the NS1 and NP1 genes were used. Amplification products from positive samples were cloned using a Topo TA Cloning Kit (Invitrogen, Carlsbad, CA, USA), for use as positive controls in PCR.
Most amplified fragments were purified and sequenced; any amplification products not sequenced were confirmed as true positives by testing against an aliquot of the sample. The sequences obtained from HBoV positive samples were aligned with clustal w (EMBL-EBI, European Bioinformatics Institute, Heidelberg, Germany).
Statistical methods
A chi-squared test was applied to compare the age distribution of virus-positive children, significance being fixed at the 5% level. The analysis was performed using spss v.13AE0 (SPSS Inc., Chicago, Illinois, USA) for Windows.
Results
Respiratory virus detection
Nasal washings were collected from 415 children hospitalized for ARIs between November 2004 and May 2007; the children's median age was 4AE5 months (range 0-169 months). The results and percentages of virus detection are shown in Table 1 ; the most common agent was RSV, identified in 120 samples (28AE9%), followed by rhinovirus (found in 40 samples, 9AE6%).
Human bocavirus was detected in 34 respiratory samples (8AE2%), 21 (61AE8%) of which harbored an additional respiratory virus. Human bocavirus was identified in specimens taken from autumn to early summer throughout the study period ( Figure 1 shows the age distribution in percentage of the virus-positive children: RSV was most frequently detected in 0-to 3-month-old children (P < 0AE01 for comparison in chi-squared test with every virus); rhinovirus, PIV1-3 and influenza rates of infection were similar in all age groups. Human bocavirus infection showed an age distribution characterized by the highest infection rates at 4-12 months (case distribution by patient age in chi-squared test: P < 0AE05 HBoV versus RSV, rhinovirus and influenza A; P = 0AE09 HBoV versus PIV1-3).
HBoV and respiratory diseases
During the study period, 121 ⁄ 204 (59AE3%) children hospitalized for bronchiolitis tested positive for at least one In 67 (44AE1%) of the 152 children hospitalized for pneumonia, a viral pathogen was identified; again, the most common agent was RSV (23 children; 15AE1%), with rhinovirus ranked second (14 children; 9AE2%). Human bocavirus was detected in nine children (5AE9%); of these, five (55AE6%) were co-infected with other viruses and four were single infections that occurred in March 2005. In addition, a single HBoV infection was detected in an atopic child with an episode of wheezing bronchitis.
Sequence data from HBoV identified in the single infections of pneumonia and bronchiolitis (March 2005 and January ⁄ February 2007, respectively) were aligned and compared with each other and with other HBoV infections found in other periods but no differences were observed in the amino acid sequences.
Between November 2006 and May 2007, in the framework of an ongoing study of immune response to respiratory viruses, venous samples were taken from all children hospitalized with a clinical diagnosis of bronchiolitis. Plasma samples from eight HBoV-infected children (five single infections and three co-infected with RSV) were tested by HBoV PCR but none was positive.
During this study, patients were also examined 7-10 days after recovery from respiratory symptoms and second nasal washings were obtained. The second nasal washings from children with HBoV infections in their first specimens tested negative to both HBoV PCRs.
Bocavirus in children without respiratory diseases
During the period from November 2006 to May 2007, nasal washings obtained from 21 children hospitalized for non-respiratory illness at the same institution were tested for the presence of respiratory viruses; the children's median age was 3 months (range 0-124 months). Only three children tested positive for respiratory viruses, two for HBoV and one for rhinovirus. One of the HBoV positive children had gastroenteric symptoms and the other had a clinical diagnosis of Exanthema subitum.
Discussion
During the study period, HBoV was the third most frequently found viral agent (Table 1 ) in children hospitalized for ARI, which is consistent with other recent reports. 7, 8 The HBoV distribution found in Rome is greater than that previously reported in Italian children with respiratory diseases, 9 but lower than that reported in nearby European countries. 10, 11 The HBoV infections were equally distributed between male and female children (exactly 1:1) and most occurred (88%) in the first year of life similarly to RSV (Fig. 1) ; nonetheless, HBoV case distribution significantly differed from the other respiratory viruses tested, in percentages at 4-12 months of age.
Any seasonal prevalence of HBoV infections was not obvious because of the small number of samples collected in summer; nevertheless, there were clusters of cases in winter ⁄ early spring (Fig. 2) . The samples in which HBoV was the only pathogen identified seem to indicate an etiological role for HBoV in pneumonia and bronchiolitis, as most other respiratory viral agents were excluded.
Various percentages of HBoV co-infection (11-90%) have been reported previously by other researchers; 8, 12, 13 however, co-infection rates consistent with our study have been reported in studies that used sensitive and comprehensive diagnostic tests. 13, 14 Undoubtedly, the HBoV rate of co-infection is higher than for other respiratory viruses, which could, in principle, either be because of the high incidence of HBoV in mild or asymptomatic upper respiratory infections in children or to the long shedding period or to reactivation after prior acute infections. In an attempt to clarify this, HBoV was sought for in HBoV-infected children after they had recovered from respiratory disease, and in hospitalized children with no respiratory symptoms. Human bocavirus was no longer detectable in the second nasal washings taken 8-12 days after the first in HBoVpositive children, suggesting a limited period of viral shedding in children with bronchiolitis. In a recent report, 15 persistent HBoV shedding for over a month was observed in patients with significant underlying diseases; however, follow-up tests were not performed in otherwise healthy children. Differences between studies could, perhaps, be accounted for by the fact that this study did not include children with underlying medical problems that could cause immune suppression and prolonged HBoV shedding. Several studies reported no or few cases of HBoV infections in asymptomatic populations or differently symptomatic control populations but often without age matching and using different types of specimens. 16 In the present study, children hospitalized for non-respiratory diseases were tested for HBoV, using the same type of specimen, taken by the same physicians, for several months during the study period. Human bocavirus was detected in 2 ⁄ 21 children; these patients had symptoms (gastroenteritis or exanthema) similar to those described previously in HBoV infections. [17] [18] [19] There are a number of possibilities that could account for these non-respiratory HBoV infections: hospitalization due to an HBoV-associated disease; HBoV infection before hospitalization, together with other pathogens; HBoV nosocomially acquired, as reported in infants hospitalized since birth. 18 In this study, HBoV was not detectable in the plasma of eight children affected with bronchiolitis, during HBoV acute infection. An Italian paper 9 reported HBoV viremia in only one child with gastroenteric symptoms, while two patients with respiratory disease tested negative. On the other hand, HBoV was detected in 53% of 43 acute-phase serum samples and in 19% of the 43 convalescent-phase serum samples from wheezing children;
14 the authors concluded that the occurrence of HBoV viremia was associated with HBoV high viral load in respiratory samples and linked in time with episodes of acute wheezing. More series of samples, with accurate quantitative analysis of HBoV DNA, will be required to clarify the issue of HBoV localized or systemic infection during ARI.
As HBoV was the sole viral pathogen detected in cases of pneumonia and bronchiolitis that had been tested for nearly all respiratory viruses, HBoV is most likely to be the agent responsible for these low-respiratory tract diseases.
In principle, some cases attributed to HBoV could be due to bacterial co-infections, as in this study, like in most others on ARI in children, bacteria were not searched for. However, the clinical data of our HBoV-infected patients and the epidemiology of pneumonia and bronchiolitis (especially below 1 year of age) do not point to bacterial infections.
In order to investigate the possibility of a common source for HBoV infection in those children with pneumonia and bronchiolitis who were temporally related, the sequencing data of NS1 and NP1 amplified fragments were compared. No differences in the amino acid sequences were found, possibly due to low variability in HBoV in NS1 and NP1 genes. In fact, only two closely related genotypes have so far been described and most nucleotide differences are in the VP1 ⁄ VP2 genes. 18, 20 In conclusion, these data together seem to indicate that HBoV is a widely circulating respiratory virus that infects patients mainly in the first year of life, probably causing subclinical manifestations and occasionally severe respiratory diseases, such as pneumonia and bronchiolitis. Nevertheless, because of its high prevalence in children, HBoV's etiological role cannot definitely be proven without isolating the virus and testing for immunity. Future prospective studies using standardized procedures for sampling and quantitative detection of viral particles are essential to study HBoV's pathogenicity and biological properties, and eventually to establish a correlation between viral load and the severity of clinical symptoms.
